"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
| Descriptor ID |
D000069474
|
| MeSH Number(s) |
D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
|
| Concept/Terms |
Sofosbuvir- Sofosbuvir
- 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
PSI 7977- PSI 7977
- 7977, PSI
- PSI7977
- PSI-7977
|
Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".
Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".
This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sofosbuvir" by people in Profiles.
-
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. J Antimicrob Chemother. 2022 09 30; 77(10):2706-2712.
-
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar. J Viral Hepat. 2021 01; 28(1):147-158.
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
-
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17; 370(16):1483-93.
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15; 370(20):1879-88.
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16; 370(3):211-21.